ReVenG: Retreatment with venetoclax plus obinutuzumab in patients with relapsed CLL
Venetoclax plus obinutuzumab has proved to be effective as frontline therapy in patients with Chronic Lymphocytic Leukemia (CLL). In this MEDtalk, Matthew S. Davids presents a trial-in-progress, investigating retreatment responses with venetoclax plus obinutuzumab in patients with relapsed CLL. Matthew is hoping for the results to support a future retreatment regimen for this group of patients.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.